Management of Patients with Heparin-induced Thrombocytopenia: Focus on Recombinant Hirudin

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2001 Jan 13

PMID 11155194

Citations 3

Authors

N Lubenow

A Greinacher

Affiliations

Soon will be listed here.

Citing Articles

Thrombin inhibitors from different animals.

Tanaka-Azevedo A, Morais-Zani K, Torquato R, Tanaka A J Biomed Biotechnol. 2010; 2010:641025.

PMID: 20976270 PMC: 2953280. DOI: 10.1155/2010/641025.

Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After....

Ohman E, Granger C, Rice L, Abrams C, Becker R, Berger P J Thromb Thrombolysis. 2005; 19(1):11-9.

PMID: 15976962 DOI: 10.1007/s11239-005-0850-7.

Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Leo A, Winteroll S Clin Diagn Lab Immunol. 2003; 10(5):731-40.

PMID: 12965896 PMC: 193890. DOI: 10.1128/cdli.10.5.731-740.2003.

References

Greinacher A, Eckhardt T, Mussmann J, MUELLER-ECKHARDT C . Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res. 1993; 71(2):123-6. DOI: 10.1016/0049-3848(93)90178-q. View

Hursting M, Alford K, Becker J, Brooks R, Joffrion J, Knappenberger G . Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997; 23(6):503-16. DOI: 10.1055/s-2007-996128. View

Vanholder R, DHondt A . Recombinant hirudin: clinical pharmacology and potential applications in nephrology. BioDrugs. 2007; 11(6):417-29. DOI: 10.2165/00063030-199911060-00006. View

Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y . Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 1995; 50(1):20-5. DOI: 10.1002/ajh.2830500105. View

Agnelli G, Iorio A, De Angelis V, Nenci G . Dermatan sulphate in heparin-induced thrombocytopenia. Lancet. 1994; 344(8932):1295-6. DOI: 10.1016/s0140-6736(94)90780-3. View

Riess F, Potzsch B, Bader R, Bleese N, Greinacher A, Lower C . A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg. 1996; 10(5):386-8. DOI: 10.1016/s1010-7940(96)80100-x. View

Magnani H . Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993; 70(4):554-61. View

Eichler P, Friesen H, Lubenow N, Jaeger B, Greinacher A . Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000; 96(7):2373-8. View

WALLIS D, Lewis B, Walenga J . Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspective. Semin Thromb Hemost. 1999; 25 Suppl 1:3-7. View

10.

Insler S, Kraenzler E, Bartholomew J, Kottke-Marchant K, Lytle B, Starr N . Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthesiology. 1997; 86(2):495-8. DOI: 10.1097/00000542-199702000-00026. View

11.

KORNALIK F, Blomback B . Prothrombin activation induced by Ecarin - a prothrombin converting enzyme from Echis carinatus venom. Thromb Res. 1975; 6(1):57-63. DOI: 10.1016/0049-3848(75)90150-4. View

12.

Madei W, Klieser H, Hoerauf K . [Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation]. Dtsch Med Wochenschr. 1999; 124(16):487-90. DOI: 10.1055/s-2007-1024348. View

13.

Eriksson B, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C . Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997; 79(3):326-33. DOI: 10.2106/00004623-199703000-00002. View

14.

Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, DaCosta A . Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost. 1999; 82(3):1199-200. View

15.

Nowak G, Bucha E, Brauns I, Czerwinski R . Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr. 1997; 109(10):354-8. View

16.

Warkentin T . Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol. 1998; 35(4 Suppl 5):17-25; discussion 35-6. View

17.

Meuleman D . Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis. 1992; 22(2):58-65. DOI: 10.1159/000216296. View

18.

Huhle G, Hoffmann U, Song X, Wang L, Heene D, Harenberg J . Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol. 1999; 106(1):195-201. DOI: 10.1046/j.1365-2141.1999.01532.x. View

19.

Ganzer D, Gutezeit A, Mayer G . [Potentials risks in drug prevention of thrombosis--low-molecular-weight heparin versus standard heparin]. Z Orthop Ihre Grenzgeb. 1999; 137(5):457-61. DOI: 10.1055/s-2008-1037391. View

20.

Warkentin T, Hayward C, Boshkov L, Santos A, Sheppard J, Bode A . Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994; 84(11):3691-9. View